Skip to main
VCEL

Vericel (VCEL) Stock Forecast & Price Target

Vericel (VCEL) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Vericel Corp is poised for robust financial growth, with projected revenue for 4Q25 estimated at $84.8 million, representing a 26% increase quarter-over-quarter. The MACI product line is anticipated to experience volume growth in the low-to-mid teens, driven by a significant conversion rate of approximately 31.6% for biopsies to MACI treatments. Furthermore, the combination of an annual average selling price (ASP) increase of 300 to 500 basis points coupled with a compound annual growth rate (CAGR) of 14.8% for MACI volume suggests sustainable revenue growth in the high teens for the foreseeable future.

Bears say

The negative outlook on Vericel Corp's stock is primarily driven by revised revenue expectations for its MACI product, which have been lowered by approximately 200 basis points for FY26 and FY27. Additional concerns include potential slower adoption rates for MACI and MACI Arthro, decreasing burn care sales, and possible disruptions during the expansion of the sales force. The combination of these factors raises the risk of missing top-line expectations, which could lead to shares declining to historical low valuation levels.

Vericel (VCEL) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vericel and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vericel (VCEL) Forecast

Analysts have given Vericel (VCEL) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Vericel (VCEL) has a Strong Buy consensus rating as of Jan 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $57.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $57.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vericel (VCEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.